Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 2047  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
  »  Article in PDF (225 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  References

 Article Access Statistics
    Viewed1111    
    Printed17    
    Emailed0    
    PDF Downloaded34    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
AUTHOR’S REPLY
Year : 2015  |  Volume : 63  |  Issue : 2  |  Page : 292

Authors' reply


,

Date of Web Publication5-May-2015

Correspondence Address:
Dr. Syam Krishnan
,

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.156327

Rights and Permissions



How to cite this article:
Krishnan S. Authors' reply. Neurol India 2015;63:292

How to cite this URL:
Krishnan S. Authors' reply. Neurol India [serial online] 2015 [cited 2019 Aug 19];63:292. Available from: http://www.neurologyindia.com/text.asp?2015/63/2/292/156327


Sir,

We appreciate the critical comments of the reader regarding our work "Validity of Montreal Cognitive Assessment in Non-English speaking patients with Parkinson's disease". [1] We welcome such healthy discussions and feel that such discussions contribute to the learning of all those who participate.

We would like to answer the reader's second concern first, as the answer to the first concern will be clearer after this. The reader has rightly pointed out the linguistic difference between validity and reliability, which we fully accept. In fact, MoCA-M is both valid and reliable for testing cognition in Malayalam-speaking patients with PD. A good correlation of MoCA-M scores with other established screening (MMSE) and more comprehensive (Addenbrooke's Cognitive Examination- ACE) instruments for cognitive testing supports its validity (the degree to which it measures what it is supposed to measure). The excellent test-retest performance and internal consistency support its reliability (the extent to which it gives results that are consistent or repeatable).

Regarding the reader's first concern about the smaller number of controls-we agree that an equal number of controls would have been ideal. However, we feel that the quality of our results is not compromised by the minimal difference in numbers (60 Vs 70), as the primary aims (testing the metric properties and thereby, validity and reliability of MoCA-M for use in Parkinson's disease patients) of the study do not rely much on the comparison between cases and controls. For the same reason, we are of the opinion that the degree of matching achieved with regard to the age and level of education, mentioned in the first paragraph under "Results" would suffice. The increased risk of cognitive dysfunction in PD patients and the increasing risk with its duration have been established by numerous earlier studies. The significantly worse performance of our PD patients in MoCA-M (paralleling the performance in MMSE and ACE) compared to controls (who were not significantly different from them with regard to age or level of education) thus gives additional support to its validity.

 
 » References Top

1.
Krishnan S, Justus S, Meluveettil R, Menon RN, Sarma SP, Kishore A. validity of montreal cognitive assessment in non-english speaking patients with parkinson's disease. Neurol India 2015;63:63-7.  Back to cited text no. 1
[PUBMED]  Medknow Journal  




 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow